Clinical Trials

Accomplished Trials

A study to evaluate the safety and efficacy of biosimilar cetuximab in patients with locoregionally advanced or recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
A randomized, double-blind, study to compare efficacy, safety, and biosimilar pembrolizumab in adult participants with untreated metastatic non-squamous non-small cell lung cancer.
A Phase 1, First in Human Study Preliminary Antitumor Activity of HPK1 Inhibitor Alone and in Combination with Pembrolizumab or Atezolizumab in Subjects with Advanced Solid Tumors and Lymphomas.
A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Biosimilar Pertuzumab (ENZENE) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer.

Ongoing Trials

A Phase 2 study to evaluate the activity of Gamma Delta (γδ) T cells in relapsed refractory solid tumors & lymphomas
A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer (NSCLC both adenocarcinoma and squamous) receiving new molecule in combination with pembrolizumab and standard chemotherapy.
A Randomised, Open-Label, Phase III Study of a new molecule compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Phase 1, Open Label, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of New Oral Molecule in Patients with Relapsed Advanced Lymphoma & Leukemia.
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH)
Study Evaluating the Safety, of New Oral Molecule in Patients with Relapsed Advanced Lymphoma & Leukemia.
A Phase 1, Open Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of an New Oral molecule in Patients with Relapsed / Advanced Solid tumors.
A Phase 1, Open Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of an New Oral molecule in Patients with Relapsed / Refractory Multiple Myeloma.
A study evaluating circulating extracellular RNA as biomarker for ovarian cancer.
A Phase III, Randomized, Open-Label Study Evaluating Efficacy And Safety Of a New Oral molecule Compared With Fulvestrant, Both Combined With A CDK4/6 Inhibitor, In patients with estrogen Receptor Positive, HER2-Negative Advanced Breast Cancer With Resistance To Prior adjuvant endocrine Therapy.
A study to explore the efficacy and safety of gamma delta T cells with
metronomic therapy in resectable head and neck cancers undergoing salvage
surgery
A Randomized, double-blind, Multicenter Phase III Clinical Study to assess the efficacy and safety of a new Immunotherapy plus Platinum based Doublet Chemotherapy versus Placebo Plus Platinum-based Doublet Chemotherapy as Neoadjuvant/adjuvant therapy in Subjects with resectable stage IIIA and IIIB Non-small Cell lung cancer.
A multi-centre, open label, balanced, randomised, two-treatment, two period, twosequence, two-way crossover, multiple-dose, steady state, pharmacokinetic endpoint bioequivalence study of niraparib tablets 2×100 mg of Natco Pharma Ltd. (test product) against Zejula (niraparib) tablet 2×100 mg of GlaxoSmithKline (Ireland) (reference product) under fasting conditions in female participants with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy
A phase III, prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of proposed biosimilar Nivolumab versus innovator Nivolumab in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.
A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of proposed biosimilar Pembrolizumab versus innovator Pembrolizumab in combination with pemetrexed and platinum based chemotherapy in adult patients with Metastatic Non-Small Cell Lung Cancer.

Join Trial

Fill in the details below.

Clinical Trials

Accomplished Trials

Ongoing Trials

Join Trial

Quick Links

Therapies

Reach Us